Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elahe Mostaghel

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
International Journal of Preventive Medicine|July 25, 2012
Preventive Therapy of Experimental Colitis with Selected iron Chelators and Anti-oxidantsMohsen Minaiyan, Elahe Mostaghel, Parvin Mahzouni
Cancer Research|October 14, 2010
Intraprostatic steroidogenic enzymes - letterElahe Mostaghel, Peter S Nelson, Colleen Nelson, et al.
The Journal of Steroid Biochemistry and Molecular Biology|June 25, 2018
11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancerMonique Barnard, Jonathan L Quanson, Elahe Mostaghel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2009
Genomic strategy for targeting therapy in castration-resistant prostate cancerPrateek Mendiratta, Elahe Mostaghel, Justin Guinney, et al.
Chemico-Biological Interactions|December 17, 2014
The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancerDaniel Tamae, Elahe Mostaghel, Bruce Montgomery, et al.
Plos One|October 8, 2013
A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumorsXiaoyu Qu, Grace Randhawa, Cynthia Friedman, et al.
Molecular Cancer Research : MCR|March 16, 2013
PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortalityEric G Bluemn, Elysia Sophie Spencer, Brigham Mecham, et al.
The Journal of Clinical Endocrinology and Metabolism|March 28, 2013
Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivationJames P Dean, Cynthia C Sprenger, Junxiang Wan, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2006
A molecular correlate to the Gleason grading system for prostate adenocarcinomaLawrence True, Ilsa Coleman, Sarah Hawley, et al.
JAMA|November 16, 2006
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trialLeonard S Marks, Norman A Mazer, Elahe Mostaghel, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
International Journal of Preventive Medicine|July 25, 2012
Preventive Therapy of Experimental Colitis with Selected iron Chelators and Anti-oxidantsMohsen Minaiyan, Elahe Mostaghel, Parvin Mahzouni
Cancer Research|October 14, 2010
Intraprostatic steroidogenic enzymes - letterElahe Mostaghel, Peter S Nelson, Colleen Nelson, et al.
The Journal of Steroid Biochemistry and Molecular Biology|June 25, 2018
11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancerMonique Barnard, Jonathan L Quanson, Elahe Mostaghel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2009
Genomic strategy for targeting therapy in castration-resistant prostate cancerPrateek Mendiratta, Elahe Mostaghel, Justin Guinney, et al.
Chemico-Biological Interactions|December 17, 2014
The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancerDaniel Tamae, Elahe Mostaghel, Bruce Montgomery, et al.
Plos One|October 8, 2013
A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumorsXiaoyu Qu, Grace Randhawa, Cynthia Friedman, et al.
Molecular Cancer Research : MCR|March 16, 2013
PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortalityEric G Bluemn, Elysia Sophie Spencer, Brigham Mecham, et al.
The Journal of Clinical Endocrinology and Metabolism|March 28, 2013
Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivationJames P Dean, Cynthia C Sprenger, Junxiang Wan, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2006
A molecular correlate to the Gleason grading system for prostate adenocarcinomaLawrence True, Ilsa Coleman, Sarah Hawley, et al.
JAMA|November 16, 2006
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trialLeonard S Marks, Norman A Mazer, Elahe Mostaghel, et al.
Pageof 2